Cargando…
Inhibitory G proteins and their receptors: emerging therapeutic targets for obesity and diabetes
The worldwide prevalence of obesity is steadily increasing, nearly doubling between 1980 and 2008. Obesity is often associated with insulin resistance, a major risk factor for type 2 diabetes mellitus (T2DM): a costly chronic disease and serious public health problem. The underlying cause of T2DM is...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4081554/ https://www.ncbi.nlm.nih.gov/pubmed/24946790 http://dx.doi.org/10.1038/emm.2014.40 |
_version_ | 1782324120447352832 |
---|---|
author | Kimple, Michelle E Neuman, Joshua C Linnemann, Amelia K Casey, Patrick J |
author_facet | Kimple, Michelle E Neuman, Joshua C Linnemann, Amelia K Casey, Patrick J |
author_sort | Kimple, Michelle E |
collection | PubMed |
description | The worldwide prevalence of obesity is steadily increasing, nearly doubling between 1980 and 2008. Obesity is often associated with insulin resistance, a major risk factor for type 2 diabetes mellitus (T2DM): a costly chronic disease and serious public health problem. The underlying cause of T2DM is a failure of the beta cells of the pancreas to continue to produce enough insulin to counteract insulin resistance. Most current T2DM therapeutics do not prevent continued loss of insulin secretion capacity, and those that do have the potential to preserve beta cell mass and function are not effective in all patients. Therefore, developing new methods for preventing and treating obesity and T2DM is very timely and of great significance. There is now considerable literature demonstrating a link between inhibitory guanine nucleotide-binding protein (G protein) and G protein-coupled receptor (GPCR) signaling in insulin-responsive tissues and the pathogenesis of obesity and T2DM. These studies are suggesting new and emerging therapeutic targets for these conditions. In this review, we will discuss inhibitory G proteins and GPCRs that have primary actions in the beta cell and other peripheral sites as therapeutic targets for obesity and T2DM, improving satiety, insulin resistance and/or beta cell biology. |
format | Online Article Text |
id | pubmed-4081554 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
publisher | Nature Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-40815542014-07-10 Inhibitory G proteins and their receptors: emerging therapeutic targets for obesity and diabetes Kimple, Michelle E Neuman, Joshua C Linnemann, Amelia K Casey, Patrick J Exp Mol Med Review The worldwide prevalence of obesity is steadily increasing, nearly doubling between 1980 and 2008. Obesity is often associated with insulin resistance, a major risk factor for type 2 diabetes mellitus (T2DM): a costly chronic disease and serious public health problem. The underlying cause of T2DM is a failure of the beta cells of the pancreas to continue to produce enough insulin to counteract insulin resistance. Most current T2DM therapeutics do not prevent continued loss of insulin secretion capacity, and those that do have the potential to preserve beta cell mass and function are not effective in all patients. Therefore, developing new methods for preventing and treating obesity and T2DM is very timely and of great significance. There is now considerable literature demonstrating a link between inhibitory guanine nucleotide-binding protein (G protein) and G protein-coupled receptor (GPCR) signaling in insulin-responsive tissues and the pathogenesis of obesity and T2DM. These studies are suggesting new and emerging therapeutic targets for these conditions. In this review, we will discuss inhibitory G proteins and GPCRs that have primary actions in the beta cell and other peripheral sites as therapeutic targets for obesity and T2DM, improving satiety, insulin resistance and/or beta cell biology. Nature Publishing Group 2014-06 2014-06-20 /pmc/articles/PMC4081554/ /pubmed/24946790 http://dx.doi.org/10.1038/emm.2014.40 Text en Copyright © 2014 KSBMB. http://creativecommons.org/licenses/by-nc-nd/3.0/ This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivs 3.0 Unported License. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-nd/3.0/ |
spellingShingle | Review Kimple, Michelle E Neuman, Joshua C Linnemann, Amelia K Casey, Patrick J Inhibitory G proteins and their receptors: emerging therapeutic targets for obesity and diabetes |
title | Inhibitory G proteins and their receptors: emerging therapeutic targets for obesity and diabetes |
title_full | Inhibitory G proteins and their receptors: emerging therapeutic targets for obesity and diabetes |
title_fullStr | Inhibitory G proteins and their receptors: emerging therapeutic targets for obesity and diabetes |
title_full_unstemmed | Inhibitory G proteins and their receptors: emerging therapeutic targets for obesity and diabetes |
title_short | Inhibitory G proteins and their receptors: emerging therapeutic targets for obesity and diabetes |
title_sort | inhibitory g proteins and their receptors: emerging therapeutic targets for obesity and diabetes |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4081554/ https://www.ncbi.nlm.nih.gov/pubmed/24946790 http://dx.doi.org/10.1038/emm.2014.40 |
work_keys_str_mv | AT kimplemichellee inhibitorygproteinsandtheirreceptorsemergingtherapeutictargetsforobesityanddiabetes AT neumanjoshuac inhibitorygproteinsandtheirreceptorsemergingtherapeutictargetsforobesityanddiabetes AT linnemannameliak inhibitorygproteinsandtheirreceptorsemergingtherapeutictargetsforobesityanddiabetes AT caseypatrickj inhibitorygproteinsandtheirreceptorsemergingtherapeutictargetsforobesityanddiabetes |